Navigation Links
Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Date:7/22/2008

to help manage the potential risks that come with prolonged hyperglycemia," said Dr. Bergenstal. "The Adjust to Target trial demonstrated that basal-bolus insulin therapy may be an effective option for the many people with type 2 diabetes who are not achieving glycemic targets with their current insulin regimen."

About the Trial

Study participants were 28-71 years old, had type 2 diabetes for greater than or equal to 6 months and mean +/- SD A1C values of 8.1 +/- 0.9% (Simplified Algorithm) and 8.3 +/- 0.9% (Carb Counting Algorithm) at screening. They had taken greater than or equal to 2 insulin injections/day (36 percent on 2 injections, 64 percent on more than 2 injections) +/- metformin (one-third were on metformin), for greater than or equal to 3 months before study entry. Upon entry into the study, 37 percent were using Lantus(R) and at least one injection of a rapid-acting insulin analog, 36 percent were using a pre-mixed insulin and the remainder were on a combination of various other diabetes treatment regimens.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin -- the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed.

At the same time, more than 40 percent of those diagnosed are not achieving the blood sugar control target of A1C <7 percent recommended by the American Diabetes Association (ADA). The A1C test measures average blood glucose levels over a two- to three-month period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the live
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of 18,200,000 shares of its common stock in an ... of $11.00 per share, before underwriting discounts. J.P. Morgan, ... as joint book-running managers for the offering. Piper ... for the offering. Avanir has granted the underwriters a ...
(Date:9/23/2014)... 2014  Echo Therapeutics, Inc. (NASDAQ: ... that, as it believes that its current liquidity ... 30, 2014, it has suspended its product development, ... conserve its liquidity and capital resources. ... Echo,s current financial position, funding alternatives, and projected ...
(Date:9/23/2014)... Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe ... Italy , UK, Spain ) Summary GBI ... Europe ( Germany , France , ... analysis of the transcatheter heart valves market in Europe . ... period and key company share data by revenue in 2013 for the following ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3Echo Therapeutics Suspends Operations To Conserve Liquidity 2Echo Therapeutics Suspends Operations To Conserve Liquidity 3Echo Therapeutics Suspends Operations To Conserve Liquidity 4Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2
... LAUSANNE, Switzerland, October 15 ... integrated molecular and,immunodiagnostics based on its proprietary micro-technology platform, ... financing round. The,Company raised EUR 10 million ( USD ... , The deal was led ...
... Ganey Associates, Inc. today announced a broad partnership with ... help measure and improve satisfaction and engagement among patients, ... on October 1, 2009. , HMA owns and operates ... licensed beds, in non-urban communities located throughout the United ...
Cached Medicine Technology:Biocartis Raises EUR10 Million in Series A Financing Round 2Biocartis Raises EUR10 Million in Series A Financing Round 3Press Ganey Partners With Health Management Associates 2
(Date:9/23/2014)... 24, 2014 Menopause can cause ... roughly half of women, menopause can trigger debilitating ... commonly associated with major depressive disorder. These ... disturbances, memory loss, and fatigue. While hormone ... effects and high cost make them an unsuitable ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 The ... moderate rate over the past five years. Growth in ... consciousness has encouraged Canadians to consume more fish and ... encouraged food retailers and food-service establishments to increase their ... industry revenue. Additionally, strong economic growth in much of ...
(Date:9/23/2014)... Mo. Infants, vocalizations throughout the first year ... and cooing to forming syllables and first words. ... amount of vocalizations may differ between hearing and ... that infant vocalizations are primarily motivated by infants, ... with profound hearing loss who received cochlear implants ...
(Date:9/23/2014)... NIH TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF ... WHAT: , The National Institutes of Health is ... available scientific evidence on the long-term effectiveness and potential ... be among the nation,s top experts in the field ... as well as key NIH scientists who focus on ...
(Date:9/23/2014)... Diego, CA (PRWEB) September 23, 2014 ... daily regarding all the latest information from the FDA ... on September 5, that its Private Label Jalapeno Bagels ... and small stones. Publix Jalapeno Bagels were ... the bakery department. , Taking into consideration the ...
Breaking Medicine News(10 mins):Health News:Pristiq Discounts Now Available from MedicationDiscountCard.com To Help Ease Menopause Symptoms 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... American Cancer Society, the largest non-government, not-for-profit funding source ... 152 new national research and training grants totaling $50,717,000 ... The grants, primarily to early career researchers, cover a ... from whether cadmium exposure increases the risk of endometrial ...
... pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several ... treated as medical problems. They,ve been "medicalized." In the ... of Social Science and Medicine , Brandeis researchers ... and a handful of other common conditions on escalating ...
... Best ... specialize in the R&D and distribution of innovative ophtalmic products to compensate for presbyopia ... High Definition reading glasses named Varionet. , ... (PRWEB) May 17, 2010 -- Best Vision International (BVI) of ...
... , This release is available in ... The world,s biggest investigation on possible links between cell ... a Canadian scientist who collaborated on the Interphone International ... of Montreal and an epidemiologist at the University of ...
... ... (ARC) program makes cutting-edge nanomaterials processing equipment more accessible and valuable , ... Newton, MA ... Microfluidizer(R) high shear fluid processors, has initiated a formal collaboration program to further ...
... ... Treatment Helps Patients Reverse Sun Damage and Restore the Health of Their Skin without ... ... extensive sun damage, resulting in wrinkles, sagging, age spots, discoloration and other unsightly symptoms. ...
Cached Medicine News:Health News:American Cancer Society awards 152 new research and training grants 2Health News:American Cancer Society awards 152 new research and training grants 3Health News:American Cancer Society awards 152 new research and training grants 4Health News:American Cancer Society awards 152 new research and training grants 5Health News:American Cancer Society awards 152 new research and training grants 6Health News:The cost of medicalizing human conditions 2Health News:Introducing a New Generation of Reading and Computer Glasses 2Health News:Introducing a New Generation of Reading and Computer Glasses 3Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 2Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 3Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 4Health News:Epione Reveals a &#8216;Bright' New Solution for Dull, Sun Damaged Skin 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: